定期检测血清HBV-DNA水平预测干扰素治疗慢性乙型肝炎的疗效

目的:研究干扰素α-2b治疗慢性乙型病毒性肝炎(以下简称慢性乙肝)期间,患者血清中HBV-DNA定量的动态变化与疗效的关系。方法:42例慢性乙肝患者肌肉注射干扰素α-2b每次3 m IU,疗程6个月。定期检测患者血清中HBV-DNA定量和丙氨酸转氨酶(ALT)变化。结果:完全应答组治疗1个月后,患者血清HBV-DNA定量显著降低,明显低于部分应答组和无应答组(P<0.05)。且完全应答组患者治疗1个月后,血清中HBV-DNA定量下降均>2log,通过分析表明用干扰素-α2b治疗1个月后若患者血清中HBV-DNA定量下降>2 log,则提示干扰素α-2b的疗效好;另外治疗前ALT高水平与其疗效好亦相关。结论:患者治疗1个月后血清中HBV-DNA定量是预测干扰素-α2b疗效的重要因素。

Serum HBVDNA level can predict treatment effectiveness in patients with chronic hepatitis B using interferon α-2b

Objective:To evaluate the correlation between the efficacy of interferon α-2b and the kinetics of viral load in serum in patients with chronic hepatitis B.Methods:The authors conducted a trial including 42 patients with chronic hepatitis B.Patients were treated with interferon α-2b for 6 months.Viral kinetics were assessed by serial quantitive measurements of HBVDNA.Results:A significant decline of serum HBV-DNA was seen after interferon α-2b treatment for 1 month in complete responders than partial responders and no-responders.After 1 month of treatment,HBV-DNA level was declined in excess of 2 log in complete responders.analysis suggested that the decline in excess of 2 log of serum HBV-DNA after 1 month of interferon α-2b treatment was associated with better efficacy;Higher baseline ALT was also correlated with better treatment outcomes.Conclusion:Kinetics of HBV-DNA level under interferon α-2b treatment are highly predictive of therapeutic response.